Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Sales of Investments

Cash received from selling or redeeming investments.

AlvotechNASDAQ: ALVO

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to $0

Q1 FY2026 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $5.95M.

Context

  • Sales of investments amounted to 1.0% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.49M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$5.95M— YoY
LTMMar 2026
$5.95M-45.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
5.95M USD
Year-over-year change
—

Sales of Investments vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's LTM Mar 2026 sales of investments of $5.95M is the 6th largest of the 11 companies compared; the peer median is $21M.
  • Its year-over-year change of -45.3% is the 6th highest of 7, against a peer median of -18.5%.
  • Sales of investments amounts to 1.1% of revenue for ALVO, versus a peer median of 0.1%.
ALVO Competitors Peer median
Sales of Investments for ALVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$10.68B -14.4%+27.7%68.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$77.51M -27.4%+47.8%10.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$68.17M -22.6%—8.6%
BIIBBiogen Inc.LTM Jun 2026$56.6M +458.2%-74.2%0.6%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$42M +5.0%+119.0%0.2%
ALVOAlvotechLTM Mar 2026$5.95M -45.3%—1.1%
AMGNAmgen Inc.LTM Jun 2026$0 ——0.0%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$0 ——0.0%
OGNOrganon & Co.LTM Sep 2026$0 ——0.0%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
HROWHarrow Health, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding ALVO) $21M-18.5%+37.7%0.1%

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(101.5M)(513.58M)(551.73M)(231.86M)27.92M
Depreciation & Amortization18.2M20.41M24.21M31.3M37.85M
Deferred Income Tax(47.69M)(38.07M)(99.32M)14.3M108.43M
Stock-Based Compensation010.32M18.03M7.63M17.38M
Change in Working Capital(6.81M)(47.89M)26.33M(288.64M)(117.64M)
Accounts Receivables(13.53M)(13.23M)(24.83M)(164.24M)(6.33M)
Inventory(29.41M)(32.41M)(11.3M)(49.97M)(90.13M)
Accounts Payables14.32M000(21.18M)
Other Working Capital21.81M(2.25M)62.46M(74.44M)0
Other Non-Cash Items(90.36M)256.42M270.29M230.44M(124.14M)
Operating Cash Flow(228.17M)(312.39M)(312.19M)(236.84M)(50.2M)
Capital Expenditures(40.63M)(49M)(46.47M)(57M)(64.47M)
Acquisitions (Net)00012M(14.04M)
Purchases of Investments0000(31.66M)
Sales of Investments00005.95M
Other Investing Activities(20.17M)(25.66M)(13.11M)22.79M0
Investing Cash Flow(40.63M)(63.54M)(46.34M)(18.87M)(104.22M)
Debt Repayment68.98M257.82M171.2M151.98M202.48M
Common Stock Issued185.86M9.83M136.88M150.45M78.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0157.27M(6.76M)(5.13M)(10.37M)
Financing Cash Flow254.83M424.91M301.32M297.31M270.83M
Effect of Forex Changes(161K)(113K)1.94M(1.32M)4.51M
Net Change in Cash(14.13M)48.87M(55.27M)40.27M120.93M
Free Cash Flow(268.8M)(361.39M)(358.66M)(293.84M)(114.67M)

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.